Teva launches asthma treatment inhaler with dose counter

Jan 06, 2013 (Menafn - Globes - McClatchy-Tribune Information Services via COMTEX) --Teva Pharmaceutical Industries Ltd. TEVA(tase:TEVA) unit Teva Respiratory has launched its ProAir HFA asthma treatment inhaler with a dose counter for use in patients from age four. The inhaler is for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB).....

Read more: menafn.com



Invion Ltd : Invion announces initiation of phase II asthma study

Invion Limited (ASX:IVX), a clinical-stage drug development company targeting chronic inflammation, today announced the initiation of "NIMA", a phase II clinical trial that is funded by the US National Institute of Allergy and Infectious Diseases (NIAID) to investigate the use of INV102 in patients with mild asthma.....

Information at 4-traders.com